Disc Medicine price target raised to $132 from $99 at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Disc Medicine (IRON) to $132 from $99 and keeps an Overweight rating on the shares. Disc Medicine plans to file a new drug application for oral GlyT1 inhibitor, bitopertin in erythropoietic protoporphyria and X-linked protoporphyria, rare heme diseases where patients experience debilitating pain when exposed to sunlight/ artificial light, in the second half of 2025, the analyst tells investors in a research note. The firm sees peak sales of $900M in the U.S. in 2035, up from its previous estimate of $430M.